TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses ... - Nasdaq

5 days ago · TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per …

CouponFollow Extension

$0.25
OFF

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses ... - Nasdaq

1 week from now

5 days ago · TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per …

nasdaq.com

71%
OFF

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue ...

1 week from now

5 days ago · TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 10.71% and 63.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues …

zacks.com

$0.25
OFF

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue …

1 week from now

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year …

msn.com

$1
OFF

TScan Therapeutics Reports Q3 2024 Financial Results

1 week from now

3 days ago · The company remains on track to dose its first patient with multiplex TCR-T therapy by the end of the year. Financially, TScan reported a decrease in revenue to $1.0 million for …

businessinsider.com

$0.28
OFF

TScan Therapeutics (TCRX) Earnings Date And Reports 2024

1 week from now

TScan Therapeutics issued Q2 2024 earnings on August 12, 2024, reporting an EPS of -$0.28, which topped the consensus estimate of -$0.30 by $0.02. Quarterly revenue was reported to …

marketbeat.com

71%
OFF

TScan Therapeutics, Inc. (TCRX) - Yahoo Finance

1 week from now

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 10.71% and 63.36%, …

yahoo.com

$0.25
OFF

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue ...

1 week from now

5 days ago · TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per …

tradingview.com

6%
OFF

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left In …

1 week from now

Nov 7, 2024 · TCRX. SCPH. TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares …

yahoo.com

FAQs about TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses ... - Nasdaq Coupon?

What's happening with TSCAN Therapeutics in the third quarter of 2024?

In their latest earnings report for the third quarter of 2024, TScan Therapeutics highlighted key milestones, including plans for an oral presentation at the upcoming ASH Annual Meeting and a virtual event to discuss updates on the ALLOHA Phase 1 trial. ...

How did TSCAN Therapeutics (TCRX) perform in the last trading session?

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks. ...

What information does TSCAN Therapeutics (TSC) present to its investors?

Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors. TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies, primarily for cancer treatment, with a focus on hematologic malignancies and solid tumors. ...

How many times has TSCAN Therapeutics surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates three times. TScan Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.05 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 63.36%. ...

How did TSCAN perform in Q3 2024?

Financially, TScan reported a decrease in revenue to $1.0 million for Q3 2024, down from $3.9 million in Q3 2023, attributed to the timing of research activities with Amgen. The company’s R&D expenses rose to $26.3 million, and G&A expenses increased to $7.4 million, reflecting expanded clinical activities and increased personnel costs. ...

How can investors track TSCAN Therapeutics' earnings estimate revisions?

Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for TScan Therapeutics: mixed. ...